Response to Mastrototaro and Gross
- Muriel Metzger, MD1,
- Gil Leibowitz, MD1,
- Julio Wainstein, MD2,
- Benjamin Glaser, MD1 and
- Itamar Raz, MD1
- 1Diabetes Center, Endocrinology and Metabolism Service, Hadassah University Hospital, Jerusalem, Israel
- 2Diabetes Unit, Wolfson Hospital, Holon, Israel
We thank Mastrototaro et al. (1) for their comments. For more than 30 years, development of a reliable ambulatory continuous glucose monitor has appeared to be an insurmountable technological challenge. The Medtronic MiniMed continuous glucose monitoring system (CGMS), the first commercially available system, provides retrospective analysis of glucose levels, making confirmation of unexpected findings difficult. As stated by Mastrototaro et al., when our sensor data were evaluated using correlation tests, a high degree of correlation with capillary blood measurements was found, confirming several previous reports. However, simple correlation tests …
